MK-8353 [cytosol]

Stable Identifier
Locations in the PathwayBrowser
for Species:
Literature References
PubMed ID Title Journal Year
29467321 Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Moschos, SJ, Sullivan, RJ, Hwu, WJ, Ramanathan, RK, Adjei, AA, Fong, PC, Shapira-Frommer, R, Tawbi, HA, Rubino, J, Rush, TS, Zhang, D, Miselis, NR, Samatar, AA, Chun, P, Rubin, EH, Schiller, J, Long, BJ, Dayananth, P, Carr, D, Kirschmeier, P, Bishop, WR, Deng, Y, Cooper, A, Shipps, GW, Moreno, BH, Robert, L, Ribas, A, Flaherty, KT

JCI Insight 2018
30034615 MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

Boga, SB, Deng, Y, Zhu, L, Nan, Y, Cooper, AB, Shipps, GW, Doll, R, Shih, NY, Zhu, H, Sun, R, Wang, T, Paliwal, S, Tsui, HC, Gao, X, Yao, X, Desai, J, Wang, J, Alhassan, AB, Kelly, J, Patel, M, Muppalla, K, Gudipati, S, Zhang, LK, Buevich, A, Hesk, D, Carr, D, Dayananth, P, Black, S, Mei, H, Cox, K, Sherborne, B, Hruza, AW, Xiao, L, Jin, W, Long, B, Liu, G, Taylor, SA, Kirschmeier, P, Windsor, WT, Bishop, R, Samatar, AA

ACS Med Chem Lett 2018
External Reference Information
External Reference
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!